Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Urovant Sciences, Inc.

https://urovant.com/

Latest From Urovant Sciences, Inc.

Pierre Fabre Launches Pivotal Trial Of Pioneering Prenatal Therapy

The first boy suffering from X-linked hypohidrotic ectodermal dysplasia has been injected with a protein replacement therapy developed by the French firm and the Esperare Foundation while inside his mother's womb.

Rare Diseases Clinical Trials

Dermavant Prepares For First Launch, Looking To Build A Blockbuster Psoriasis Brand

The Roivant-owned company's Vtama topical cream was approved by the US FDA with a broad label permitting use for mild, moderate or severe psoriasis.

Approvals Launches

Asia Deal Watch: Vibegron’s Vagabond Journey Continues With Eisai Acquiring Partial Asian Rights

Kyorin, Eisai build on earlier OAB deal to team on vibegron. Plus deals involving Piramal/Hemmo, ImmuneOncia/3D Medicines, Kyowa Kirin/Cerecor, Simcere/Kazia, Nippon Shinyaku/Menarini, Tarsus/LianBio

Deals M & A

Napabucasin Failure Costly, And Possibly Transformative, For Dainippon

Japanese firm’s recent decision to halt development of its lead oncology asset, gained through a multi-billion-dollar acquisition where it was the main attraction, not only has a financial cost but may prompt more strategic deal-making.

Commercial Deals
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
    • Specialty Pharmaceuticals
UsernamePublicRestriction

Register